Ibandronate binds to hydroxyapatite found in bone, and its primary effect is to inhibit osteoclast activity. This reduces bone turnover and leads to an overall increase in bone mass. The medication is taken either orally or via intravenous injection, depending on the specific needs and health conditions of the patient.
